Page last updated: 2024-12-11

bafilomycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5702538
MeSH IDM0161112

Synonyms (8)

Synonym
nsc 381866
(3z,5e,7r,8s,9s,11e,13e,15s,16r)-8-hydroxy-16-[(1s,2r,3 s)-2-hydroxy-1-methyl-3-[(2r,4r,5s,6r)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2h-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one
(3z,5e,7r,8s,9r,11e,13e,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
bafilomycin a
116764-51-3
DTXSID201015547
(5r)-2,4-dideoxy-1-c-{(2s,3r,4s)-3-hydroxy-4-[(2r,3s,4e,6e,9r,10s,11r,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-4-methyl-5-propan-2-yl-alpha-d-threo-pentopyranose
PD129842

Research Excerpts

Overview

Bafilomycin A1, which is a specific vacuolar ATPase inhibitor, was used as a control and inhibited the vesicular dopamine, glutamate, and GABA uptake.

ExcerptReferenceRelevance
"Bafilomycin A1, which is a specific vacuolar ATPase inhibitor, was used as a control and inhibited the vesicular dopamine, glutamate, and GABA uptake to the same extent."( Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter.
Fonnum, F; Fykse, EM; Roseth, S, 1995
)
1.01

Effects

ExcerptReferenceRelevance
"Bafilomycin A(1) also has no significant effect on oxygen consumption by isolated mitochondria."( Energizing an invertebrate embryo: bafilomycin-dependent respiration and the metabolic cost of proton pumping by the V-ATPase.
Covi, JA; Hand, SC,
)
0.85

Treatment

Treatment with bafilomycin A(1), an autophagy inhibitor, did not affect cardiac function in normally fed mice. But it significantly depressed cardiac function and caused significant left ventricular dilatation in the mice starved for 3 days.

ExcerptReferenceRelevance
"Treatment with bafilomycin A(1), an autophagy inhibitor, did not affect cardiac function in normally fed mice, but it significantly depressed cardiac function and caused significant left ventricular dilatation in the mice starved for 3 days."( Autophagy maintains cardiac function in the starved adult.
Fujiwara, H; Goto, K; Kanamori, H; Maruyama, R; Minatoguchi, S; Seishima, M; Takemura, G; Tsujimoto, A, 2009
)
0.69
"Treatment with bafilomycin A1, which inhibits endosomal acidification, traps the luciferase activity within endosomes."( Adaptation of Clostridium difficile toxin A for use as a protein translocation system.
Feig, AL; Kern, SM, 2011
)
0.71

Toxicity

ExcerptReferenceRelevance
"Cardiotoxicity is a predominant side-effect of nilotinib during chronic myeloid leukemia treatment."( Caspase-Independent Pathway is Related to Nilotinib Cytotoxicity in Cultured Cardiomyocytes.
Chen, Y; Li, G; Meng, Z; Wei, H; Xu, Y; Yang, Q; Zhang, C, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" We investigated the effect of inhibition of osteoclastic acidification in vivo by using the rat ovariectomy model with twice daily oral dosing of NS3696 at 50 mg/kg for 6 weeks."( Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.
Bollerslev, J; Christiansen, C; Christophersen, P; Dziegiel, MH; Gram, J; Heegaard, AM; Henriksen, K; Karsdal, MA; Martin, TJ; Schaller, S; Sørensen, MG, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (305)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.66)18.7374
1990's66 (21.64)18.2507
2000's111 (36.39)29.6817
2010's112 (36.72)24.3611
2020's14 (4.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.47 (24.57)
Research Supply Index5.75 (2.92)
Research Growth Index6.52 (4.65)
Search Engine Demand Index49.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other307 (98.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]